Literature DB >> 29324207

Oligometastatic Non-Small-Cell Lung Cancer: How Should We Define and Manage It?

David E Gerber1.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29324207      PMCID： PMC5765903          DOI： 10.1200/JOP.2017.028290

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  11 in total

1.  Tumor size, sensitivity to therapy, and design of treatment schedules.

Authors:  L Norton; R Simon
Journal:  Cancer Treat Rep       Date:  1977-10

2.  Nonsmall cell lung cancer presenting with synchronous solitary brain metastasis.

Authors:  Chaosu Hu; Eric L Chang; Samuel J Hassenbusch; Pamela K Allen; Shiao Y Woo; Anita Mahajan; Ritsuko Komaki; Zhongxing Liao
Journal:  Cancer       Date:  2006-05-01       Impact factor: 6.860

3.  Managing Patients With Oligometastatic Non-Small-Cell Lung Cancer.

Authors:  Sarah Jo Stephens; Michael J Moravan; Joseph K Salama
Journal:  J Oncol Pract       Date:  2018-01       Impact factor: 3.840

4.  Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.

Authors:  Andrew J Weickhardt; Benjamin Scheier; Joseph Malachy Burke; Gregory Gan; Xian Lu; Paul A Bunn; Dara L Aisner; Laurie E Gaspar; Brian D Kavanagh; Robert C Doebele; D Ross Camidge
Journal:  J Thorac Oncol       Date:  2012-12       Impact factor: 15.609

5.  Preoperative staging of lung cancer with combined PET-CT.

Authors:  Barbara Fischer; Ulrik Lassen; Jann Mortensen; Søren Larsen; Annika Loft; Anne Bertelsen; Jesper Ravn; Paul Clementsen; Asbjørn Høgholm; Klaus Larsen; Torben Rasmussen; Susanne Keiding; Asger Dirksen; Oke Gerke; Birgit Skov; Ida Steffensen; Hanne Hansen; Peter Vilmann; Grete Jacobsen; Vibeke Backer; Niels Maltbaek; Jesper Pedersen; Henrik Madsen; Henrik Nielsen; Liselotte Højgaard
Journal:  N Engl J Med       Date:  2009-07-02       Impact factor: 91.245

6.  Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis.

Authors:  Kyle E Rusthoven; Susan F Hammerman; Brian D Kavanagh; Michael J Birtwhistle; Mark Stares; D Ross Camidge
Journal:  Acta Oncol       Date:  2009       Impact factor: 4.089

7.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.

Authors:  J H Goldie; A J Coldman
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec

Review 8.  Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis.

Authors:  Tawee Tanvetyanon; Lary A Robinson; Michael J Schell; Vivian E Strong; Rachna Kapoor; Daniel G Coit; Gerold Bepler
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544

Review 9.  Parallel progression of primary tumours and metastases.

Authors:  Christoph A Klein
Journal:  Nat Rev Cancer       Date:  2009-04       Impact factor: 60.716

10.  Baseline tumour measurements predict survival in advanced non-small cell lung cancer.

Authors:  D E Gerber; S E Dahlberg; A B Sandler; D H Ahn; J H Schiller; J R Brahmer; D H Johnson
Journal:  Br J Cancer       Date:  2013-08-13       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.